Intercept Pharma (ICPT) Confirms U.S. Prescribing Information for Ocaliva to Reinforce Appropriate Dosing in PBC Patients with Advanced Cirrhosis
Tweet Send to a Friend
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
